Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

被引：1
|
作者：
Grivas, Petros
Laliberte, Francois
Doleh, Yunes
O'Connor, Cristi
Duh, Mei Sheng
Shenolikar, Rahul
机构：
[1] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Grp Anal Ltee, Montreal, PQ, Canada
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ONCOLOGISTS' PREFERENCES FOR FIRST-LINE (1L) TREATMENT OF LOCALLY ADVANCED/ UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA (AUC)
    Grivas, P.
    Phani, V
    Chiu, K.
    Pawar, V
    Chang, J.
    Bharmal, M.
    VALUE IN HEALTH, 2022, 25 (01) : S162 - S162
  • [2] Healthcare costs and resource utilization associated with select severe adverse events in patients with metastatic urothelial cancer treated with first-line systemic therapies
    Shenolikar, Rahul
    Laliberte, Francois
    Doleh, Yunes
    Cavanaugh, Cristi
    DerSarkissian, Maral
    Grivas, Petros
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 300 - 301
  • [3] Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy.
    Greally, Megan
    Walch, Henry S.
    Chou, Joanne F.
    Capanu, Marinela
    Kelsen, David Paul
    Ilson, David H.
    Janjigian, Yelena Yuriy
    Schultz, Nikolaus
    Ku, Geoffrey Yuyat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
    Barthelemy, Philippe
    Loriot, Yohann
    Voog, Eric
    Eymard, Jean Christophe
    Ravaud, Alain
    Flechon, Aude
    Jaillon, Christine Abraham
    Chasseray, Matthieu
    Lorgis, Veronique
    Hilgers, Werner
    Gobert, AurElien
    Le Moulec, Sylvestre
    Simon, Camille
    Nicolas, Emanuel
    Escande, Anne
    Pouessel, Damien
    Josse, Constant
    Solbes, Marie-Noelle
    Lambert, Prisca
    Thibault, Constance
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
    Grivas, P.
    Park, S. H.
    Voog, E.
    Su, W-P.
    Demey, W.
    Fong, P. C.
    Garcia, J. A.
    Jacob, N.
    Gerhold-Ay, A.
    Tyroller, K.
    Hoffman, J.
    Bellmunt, J.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1144 - S1144
  • [6] Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).
    Moon, Helen H.
    Aragon-Ching, Jeanny B.
    Thompson, Allison
    Abraham, Anup
    Vlahiotis, Anna
    Ike, Chiemeka
    Benjumea, Darrin
    Shao, Anran
    Sun, Haiyan
    Kearney, Mairead
    Gharibian, Norbek
    Hanson, Sarah
    Li, Benjamin
    Kirker, Melissa
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
    Ajmera, M.
    Chang, J.
    Hitchens, A.
    Kearney, M.
    Esterberg, E.
    Kim, R.
    Cappelleri, J.
    Devgan, G.
    Costa, N.
    Candrilli, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S715 - S716
  • [8] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
    Gupta, S.
    Climent Duran, M. A.
    Sridhar, S.
    Powles, T. B.
    Bellmunt, J.
    Tyroller, K.
    Guenther, S.
    di Pietro, A.
    Grivas, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1207 - S1207
  • [9] TREATMENT OF ADVANCED BILIARY TRACT CANCER (BTC) AFTER PROGRESSION ON FIRST-LINE (1L) SYSTEMIC THERAPY
    Danese, M.
    Lubeck, D.
    Gleeson, M.
    Bobiak, S.
    VALUE IN HEALTH, 2019, 22 : S498 - S499
  • [10] Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
    Powles, T. B.
    Sridhar, S.
    Bellmunt, J.
    Sternberg, C.
    Grivas, P.
    Hunter, E.
    Dezfouli, M.
    Salter, M.
    Powell, R.
    Dring, A.
    Green, J.
    Akoulitchev, A.
    Amezquita, R.
    Ching, K.
    Pu, J.
    Deng, S.
    di Pietro, A.
    Davis, C. B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1442 - S1442
12345